Literature DB >> 16849499

Complement activation via alternative pathway is critical in the development of laser-induced choroidal neovascularization: role of factor B and factor H.

Nalini S Bora1, Sankaranarayanan Kaliappan, Purushottam Jha, Qin Xu, Jeong-Hyeon Sohn, Dhara B Dhaulakhandi, Henry J Kaplan, Puran S Bora.   

Abstract

The objective of this study was to explore the role of classical, lectin, and alternative pathways of complement activation in laser-induced choroidal neovascularization (CNV). The classical and alternative pathways were blocked in C57BL/6 mice by small interfering RNAs (siRNA) directed against C1q and factor B, respectively. C4(-/-) mice developed CNV similar to their wild-type controls and inhibition of C1q by siRNA had no effect on the development of CNV. In contrast, CNV was significantly inhibited (p < 0.001) in C5(-/-) mice and C57BL/6 mice treated with factor B siRNA. Inhibition of the alternative pathway by factor B siRNA resulted in decreased levels of membrane attack complex and angiogenic factors-vascular endothelial growth factor and TGF-beta2. Furthermore, factor B was up-regulated in complement sufficient C57BL/6 mice at day 1 postlaser and remained elevated at day 7. Significantly reduced levels of factor H were observed at day 3 in these animals. In conclusion, our results demonstrate that activation of the factor B-dependent alternative pathway, but not the classical or lectin pathways, was essential for the development of CNV in mouse model of laser-induced CNV. Thus, specific blockade of the alternative pathway may represent a therapeutically relevant strategy for the inhibition of CNV.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16849499     DOI: 10.4049/jimmunol.177.3.1872

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  63 in total

1.  Relationship between complement membrane attack complex, chemokine (C-C motif) ligand 2 (CCL2) and vascular endothelial growth factor in mouse model of laser-induced choroidal neovascularization.

Authors:  Juan Liu; Purushottam Jha; Valeriy V Lyzogubov; Ruslana G Tytarenko; Nalini S Bora; Puran S Bora
Journal:  J Biol Chem       Date:  2011-04-22       Impact factor: 5.157

Review 2.  Animal models of age related macular degeneration.

Authors:  Mark E Pennesi; Martha Neuringer; Robert J Courtney
Journal:  Mol Aspects Med       Date:  2012-06-15

Review 3.  Sphingosine-1-phosphate antibodies as potential agents in the treatment of cancer and age-related macular degeneration.

Authors:  Roger A Sabbadini
Journal:  Br J Pharmacol       Date:  2011-03       Impact factor: 8.739

4.  Systemic human CR2-targeted complement alternative pathway inhibitor ameliorates mouse laser-induced choroidal neovascularization.

Authors:  Bärbel Rohrer; Beth Coughlin; Mausumi Bandyopadhyay; V Michael Holers
Journal:  J Ocul Pharmacol Ther       Date:  2012-02-06       Impact factor: 2.671

Review 5.  Immunopathological aspects of age-related macular degeneration.

Authors:  Mrinali Patel; Chi-Chao Chan
Journal:  Semin Immunopathol       Date:  2008-02-26       Impact factor: 9.623

Review 6.  Age-related macular degeneration and the immune response: implications for therapy.

Authors:  Robert B Nussenblatt; Frederick Ferris
Journal:  Am J Ophthalmol       Date:  2007-08-15       Impact factor: 5.258

Review 7.  Mediators of ocular angiogenesis.

Authors:  Yureeda Qazi; Surekha Maddula; Balamurali K Ambati
Journal:  J Genet       Date:  2009-12       Impact factor: 1.166

Review 8.  From compliment to insult: genetics of the complement system in physiology and disease in the human retina.

Authors:  Robert F Mullins; Alasdair N Warwick; Elliott H Sohn; Andrew J Lotery
Journal:  Hum Mol Genet       Date:  2017-08-01       Impact factor: 6.150

Review 9.  The role of complement system in ocular diseases including uveitis and macular degeneration.

Authors:  Purushottam Jha; Puran S Bora; Nalini S Bora
Journal:  Mol Immunol       Date:  2007-09       Impact factor: 4.407

Review 10.  Angiogenesis in eye disease: immunity gained or immunity lost?

Authors:  Thomas A Ferguson; Rajendra S Apte
Journal:  Semin Immunopathol       Date:  2008-02-23       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.